These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 19748436)

  • 1. Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus.
    Arhin FF; McKay GA; Beaulieu S; Sarmiento I; Parr TR; Moeck G
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):207-10. PubMed ID: 19748436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus.
    Arhin FF; Sarmiento I; Parr TR; Moeck G
    Int J Antimicrob Agents; 2012 Feb; 39(2):159-62. PubMed ID: 22070858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD; Pawlak J; Johnson LB
    Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin.
    Vidaillac C; Parra-Ruiz J; Rybak MJ
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):470-3. PubMed ID: 22018937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes.
    Arhin FF; McKay GA; Beaulieu S; Sarmiento I; Parr TR; Moeck G
    Int J Antimicrob Agents; 2009 Dec; 34(6):550-4. PubMed ID: 19818587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA).
    Arhin FF; Sarmiento I; Moeck G
    Int J Antimicrob Agents; 2013 Apr; 41(4):397-8. PubMed ID: 23374976
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of human serum albumin on oritavancin in vitro activity against enterococci.
    McKay GA; Beaulieu S; Sarmiento I; Arhin FF; Parr TR; Moeck G
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2687-9. PubMed ID: 19349514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Sweeney D; Shinabarger DL; Arhin FF; Belley A; Moeck G; Pillar CM
    Diagn Microbiol Infect Dis; 2017 Feb; 87(2):121-128. PubMed ID: 27890418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin.
    Arhin FF; Sarmiento I; Parr TR; Moeck G
    J Antimicrob Chemother; 2009 Oct; 64(4):868-70. PubMed ID: 19656783
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
    Vaudaux P; Huggler E; Arhin FF; Moeck G; Renzoni A; Lew DP
    Int J Antimicrob Agents; 2009 Dec; 34(6):540-3. PubMed ID: 19744838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
    Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J
    Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.
    Bouza E; Burillo A
    Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD; Cheung CM; Rybak MJ
    J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.
    Lin G; Pankuch G; Appelbaum PC; Kosowska-Shick K
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6251-4. PubMed ID: 25022588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters.
    Arhin FF; Tomfohrde K; Draghi DC; Aranza M; Parr TR; Sahm DF; Moeck G
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):92-5. PubMed ID: 18614315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
    Lin G; Appelbaum PC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):233-5. PubMed ID: 17997257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Domenech A; Ribes S; Cabellos C; Taberner F; Tubau F; Domínguez MA; Montero A; Liñares J; Ariza J; Gudiol F
    J Antimicrob Chemother; 2005 Oct; 56(4):709-16. PubMed ID: 16120625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus.
    Leonard SN; Rolek KM
    J Antimicrob Chemother; 2013 Mar; 68(3):644-7. PubMed ID: 23152482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.